PPCB: Propanc Biopharma Inc Net earnings per share for the last 12 months

Symbol and logo of brand Propanc Biopharma Inc. (PPCB)

Propanc Biopharma Inc (PPCB) management ensures the seamless operation of laboratories and the reconfiguration of contract lines. The company's net profit per share over 12 months visualizes the results of these activities. Meanwhile, the -260.21 level captures the current state of the metric. The business relies on an enzyme platform to drive FCF growth, utilizing outsourced clinical trials to minimize capital expenditures on plants.

PPCB (Propanc Biopharma Inc) Net earnings per share (EPS TTM) history from 08/16/2025 to 11/12/2026

Analytical breakdowns for Propanc Biopharma Inc

- share price and expert price forecast:
Stock Quotes Propanc Biopharma, Inc.|PPCB - Fair Value Consensus
- market capitalization information:
Market Valuation Propanc Biopharma Inc.|PPCB - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share Propanc Biopharma|PPCB - Book Capitalization|Market Value to Book Value Ratio propanc.com|PPCB - Aggregate Asset Value
- business debt structure and liquidity details:
Total Debt to Capital Propanc Biopharma Inc|PPCB - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Propanc Biopharma, Inc.|PPCB - Company Cumulative Debt|Debt to Book Value Propanc Biopharma Inc.|PPCB - Amount of Long-Term Liabilities|Company Short-Term Debts Propanc Biopharma|Quick Ratio propanc.com
- net income and valuation multiples indicators:
PPCB - Company Profit|Future Profit Propanc Biopharma Inc|PPCB - Company Value to Net Income|Projected Price to Earnings Propanc Biopharma, Inc.|PPCB - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Propanc Biopharma Inc.|PPCB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Propanc Biopharma|PPCB - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months propanc.com|PPCB - Earnings per share increase in current year|Earnings growth forecast for next year Propanc Biopharma Inc
Basic company analysis:propanc.com - PPCB
Manufactured products of Propanc Biopharma Inc.

Professional capital evaluates the issuer through the lens of real earnings per share. This indicator reflects annual net profit while neutralizing the impact of the total shares outstanding. By analyzing the EPS TTM dynamics of the company, an investor can discern the actual business efficiency without accounting distortions. For Propanc Biopharma Inc (PPCB), this metric reflects the monetization of synergies with international laboratories in the field of oncotherapy. Steady growth of this metric confirms the investment reliability of the asset.

Who Propanc Biopharma Inc competes with

GMAB: Net earnings per share for the last 12 months|Earnings per share for the trailing year EXEL (exelixis.com)|NUVL (Nuvalent) - Net earnings per share for the last 12 months|KYMR: Earnings per share for the last four quarters|IDYA (IDEAYA Bio) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Enliven Corp|Earnings per share for the last twelve months ORIC Pharmaceuticals (ORIC)|RLAY (relaytx.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics, Inc.)|Net earnings per share for the trailing year Tyra Biosciences Inc|Verastem Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Monte Rosa Corp|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (C4 Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics, Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc - Earnings per share for the last 12 months|Karyopharm Therapeutics Inc. - Net earnings per share for the last 12 months|Earnings per share for the trailing year BGMS|AADI: Net earnings per share for the last 12 months|Aileron Therapeutics - Earnings per share for the last four quarters|BPMC: Net earnings per share (EPS TTM)|GlycoMimetics - Earnings per share for the trailing year|SWTX (SpringWorks Therapeutics) - Net earnings per share (EPS TTM)